Indivior Pharmaceuticals (INDV) Liabilities and Shareholders Equity (2021 - 2026)
Indivior Pharmaceuticals has reported Liabilities and Shareholders Equity over the past 6 years, most recently at $1.2 billion for Q1 2026.
- For Q1 2026, Liabilities and Shareholders Equity fell 12.95% year-over-year to $1.2 billion; the TTM value through Mar 2026 reached $5.3 billion, down 7.45%, while the annual FY2025 figure was $1.2 billion, 8.74% down from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 was $1.2 billion at Indivior Pharmaceuticals, roughly flat from $1.2 billion in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $1.9 billion in Q3 2023 and troughed at $1.2 billion in Q1 2026.
- A 5-year average of $1.5 billion and a median of $1.5 billion in 2024 define the central range for Liabilities and Shareholders Equity.
- Biggest five-year swings in Liabilities and Shareholders Equity: decreased 0.62% in 2023 and later decreased 25.14% in 2024.
- Year by year, Liabilities and Shareholders Equity stood at $1.8 billion in 2022, then dropped by 0.62% to $1.8 billion in 2023, then fell by 25.14% to $1.3 billion in 2024, then fell by 8.74% to $1.2 billion in 2025, then fell by 0.33% to $1.2 billion in 2026.
- Business Quant data shows Liabilities and Shareholders Equity for INDV at $1.2 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.4 billion in Q3 2025.